Highlights
– In the RAFF4 randomized clinical trial (n=350), vernakalant converted a greater proportion of patients to sinus rhythm within 30 minutes than procainamide (62.4% vs 48.3%; adjusted absolute difference 15.0%).
– Vernakalant achieved conversion faster (mean 21.8 vs 44.7 minutes) and reduced the need for attempted electrical cardioversion (33.7% vs 44.2%).
